SeqLL, Inc. (SQL)

NASDAQ: SQL · IEX Real-Time Price · USD
0.820
0.000 (0.00%)
At close: Jun 29, 2022 10:39 AM
0.840
+0.020 (2.439%)
After-hours: Jun 29, 2022 5:53 PM EDT
0.00%
Market Cap 9.75M
Revenue (ttm) 196,744
Net Income (ttm) -3.23M
Shares Out 11.89M
EPS (ttm) -0.36
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 32,008
Open 0.820
Previous Close 0.820
Day's Range 0.755 - 0.858
52-Week Range 0.610 - 5.800
Beta n/a
Analysts Buy
Price Target 3.06 (+273.2%)
Earnings Date Aug 12, 2022

About SQL

SeqLL Inc. operates as a life sciences instrumentation and research services company worldwide. The company designs, develops, and manufactures genetic analysis technologies. It offers true single molecule sequencing (tSMS) platform, which offers a single molecule solution for DNA and RNA sequencing. The company has a collaboration agreement with Bernstein Laboratory, Ting Laboratory, The Jackson Laboratory for Genomic Medicine, Weizmann Institute of Science, True Bearing Diagnostics, Inc., and Tetracore, Inc. It serves academic and government ... [Read more...]

Industry Diagnostics & Research
IPO Date Aug 27, 2021
Employees 7
Stock Exchange NASDAQ
Ticker Symbol SQL
Full Company Profile

Financial Performance

In 2021, SeqLL's revenue was $209,995, a decrease of -36.27% compared to the previous year's $329,495. Losses were -$3.70 million, 254.3% more than in 2020.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for SQL stock is "Buy." The 12-month stock price forecast is 3.06, which is an increase of 273.17% from the latest price.

Price Target
$3.06
(273.17% upside)
Analyst Consensus: Buy
Stock Forecasts

News

SeqLL Inc. Receives Nasdaq Notification Regarding Minimum Bid Requirements

BILLERICA, Mass., June 24, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. (NASDAQ: SQL and SQLLW) (“SeqLL” or the “Company”), a technology company providing life sciences instrumentation and research services in c...

SeqLL's Single-Molecule Nucleosome Imaging Method Published in Peer Reviewed Cell Reports Journal

BILLERICA, Mass., June 13, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL; SQLLW), a technology company providing life sciences instrumentation and research services in coll...

SeqLL Provides First Quarter 2022 Financial Results and a Corporate Update

BILLERICA, Mass., May 13, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL; SQLLW), a technology company providing life sciences instrumentation and research services in colla...

6 Stocks Halted In Thursday's Session

A circuit breaker is an automatic, temporary trading halt on certain securities when the underlying stock is experiencing times of high volatility. It's a measure put in place to help restore and bring ...

Other symbols: FRGEGYROIMTEOXBR

SeqLL Announces Fourth Quarter and Year End 2021 Financial Results and Provides a Corporate Update

BILLERICA, Mass., March 30, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL; SQLLW), a technology company providing life sciences instrumentation and research services in col...

SeqLL to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest

BILLERICA, Mass., March 24, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL; SQLLW), a technology company providing life sciences instrumentation and research services for co...

SeqLL Announces Formation of Scientific Advisory Board

BILLERICA, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL; SQLLW), a technology company providing life sciences instrumentation and research services for co...

SeqLL Inc. Announces Closing of Underwriters' Option to Purchase Additional Shares of Common Stock in Connection with...

WOBURN, Mass., Sept. 29, 2021 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ:SQL; SQLLW), a development-stage life sciences instrumentation and research services company engaged in th...

SeqLL Announces Publication of a New Single-Cell Epitranscriptomic Method Powered by SeqLL's tSMS® Platform

Method developed by leading researchers at the Bernstein Laboratory and SeqLL Inc.

7 Biotech Stocks to Buy That Have Millionaire-Maker Potential

This sector is always a risky area to gamble in. If you have the stomach for it, however, these biotech stocks could see massive gains.